Angiex selected ZingPR to generate excitement and build momentum for the Phase 1 clinical trial of AGX101, a novel antibody-drug conjugate (ADC) designed to revolutionize cancer treatment by targeting tumor blood vessels. The campaign played a crucial role in communicating the potential of AGX101 to transform cancer treatment and attracting support for Angiex's mission.

WideTrial, a startup focused on expanded access programs (EAPs), partnered with ZingPR to announce its role in a major NIH-funded EAP for ALS. The challenge was to generate excitement while establishing credibility and navigating the constraints faced by many startups. How ZingPR helped WideTrial achieve significant media coverage in prominent publications.

Recently, I had the chance to work on a fascinating project: promoting a debate on aging. Not your typical PR gig, right? But that's what I love about this field—the chance to work with innovative companies tackling big challenges. My goal was simple: make this debate unmissable. And more importantly, make it matter. Because the science behind it really matters.

In this episode of "Twinning Strategy," the team discusses tips on attracting press coverage and funding. Learn how to find the right time to start PR, craft compelling stories that journalists (and investors) crave, and even turn crises into positive opportunities.

With its patented technology that can extend metalens field of view (FOV) to almost 180 degrees without sacrificing imaging quality, 2Pi Optics outperforms conventional wide-FOV refractive optics in size, weight, performance, and cost.

“… when Elenagen was added to the treatment regimen, all patients showed complete or partial regression of the primary tumor and associated metastases in the lungs, liver, lymph nodes, and bones.”

Following its recent announcement of a partnership with WTS Energy, Hiber announced an agreement with Shell that provides the energy giant with access to Hiber's satellite-connected IoT well-monitoring solution.

Optellum’s strategic collaboration agreement with the Lung Cancer Initiative at Johnson & Johnson drives media interest across the board.

Syncari wants to help marketing ops, sales ops and revops gain control of their data and put it to work with confidence.

Matt Pillar’s feature on BioCube captures how the buzzing biotech accelerator is winning the hearts and minds of Silicon Valley biotech startups.

ZingPR assisted Transform Materials with a fast-track investment announcement from Chart Industries, a major LNG equipment supplier.

Senturion+ launches an advanced, natural material called Viruend that catches and kills at least 25% more SARS-CoV-2 and other viruses than standard N95 masks.

Dr. David Soane, founder and CEO of Transform Materials, explains how his company’s technology reduces harmful greenhouse gas emissions at shale wells while yielding two valuable by-products.

With BioCube’s cool wet labs now up and running, the next wave of budding biotech companies have a good reason to locate closer to San Jose.

At hydraulic fracking wellheads, natural gas is often flared instead of collected—a colossal waste of a natural resource that increases harmful greenhouse gases.

Biovista applies AI and data science to identify two drugs as potentially effective therapies for blood clots and inflammation caused by COVID-19. That’s six treatments identified to date!